Arstat Pharmaceuticals

Executive Summary

Arstat Pharmaceuticals is a private, preclinical-stage biotech company founded in 2018 and based in San Diego, California. The company is dedicated to developing transformational women's health products, with its lead program targeting the first-ever contraceptive specifically designed for women with high BMI. This focus addresses a significant unmet need, as women with high BMI have limited contraceptive options due to efficacy and safety concerns with existing products. Arstat's mission is to address highly prevalent, under-treated reproductive conditions and disorders, positioning it as a potential leader in the women's health space. The company is currently in the preclinical stage, and its success hinges on progressing its lead candidate through development and securing partnerships or funding to advance clinical trials. While the company's specific financial details and valuation are not disclosed, its niche focus on a large underserved population presents a compelling investment thesis for early-stage investors interested in women's health innovation.

Upcoming Catalysts (preview)

• TBDPreclinical Data Readout for Lead Contraceptive Candidate50% success
• TBDSeries A Financing Round Announcement60% success
• TBDFDA Pre-IND Meeting or IND Filing40% success